Scinai Immunotherapeutics
SCNI
14 hedge funds and large institutions have $891K invested in Scinai Immunotherapeutics in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 6 closing their positions.
0.15% more ownership
Funds ownership: 1.54% → 1.69% (+0.15%)
13% less funds holding
Funds holding: 16 → 14 (-2)
17% less capital invested
Capital invested by funds: $1.08M → $891K (-$186K)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$280K |
| 2 |
Millennium Management
New York
|
+$37.4K |
| 3 |
Morgan Stanley
New York
|
+$31.1K |
| 4 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$15.6K |
| 5 |
TPWA
TRUE Private Wealth Advisors
Salem,
Oregon
|
+$9.34K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$111K |
| 2 |
Goldman Sachs
New York
|
-$103K |
| 3 |
VF
Virtu Financial
New York
|
-$70K |
| 4 |
Two Sigma Advisers
New York
|
-$42K |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$37K |
SCNI Hedge Fund Activity: Q2 2021 in Review
14 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2021, worth a combined $891K — down 17% from $1.08M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of SCNI and 4 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $280K. The largest seller was Citadel Advisors, exiting entirely with an estimated $111K sold.
- 14 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2021, down from 16 in Q1 2021.
- Funds reported $891K of Scinai Immunotherapeutics stock for Q2 2021, down 17% quarter-over-quarter.
- 4 funds opened new Scinai Immunotherapeutics positions in Q2 2021 and 6 closed out, a net change of -2 holders.
- The largest Scinai Immunotherapeutics buyer in Q2 2021 was Renaissance Technologies, an estimated $280K added.
- The largest Scinai Immunotherapeutics seller in Q2 2021 was Citadel Advisors, an estimated $111K sold.
Based on aggregated 13F filings for Q2 2021.